Cuba’s regulatory authority approves emergency use of Abdala coronavirus vaccine

Abdala, one of the five formulas developed by the Caribbean country against covid-19 and the first to reach the vaccine category, is a subunit immunogen with an intramuscular administration scheme of three doses in 28 days.

RIO DE JANEIRO, BRAZIL - Cuba's Center for the State Control of Medicines, Equipment and Medical Devices (CECMED) granted this Friday (9) authorization for emergency use of the Cuban vaccine against the Abdala coronavirus, which in its clinical trials showed an efficacy of 92.2%.

The authorization was granted "once it was confirmed that it complies with the requirements and parameters demanded in terms of quality, safety and efficacy for this type of procedure", informed the CECMED in a communiqué.

Abdala, one of the five formulas developed by the Caribbean country against Covid-19 and the first to reach the . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?